Mission Statement, Vision, & Core Values of Precision BioSciences, Inc. (DTIL)

Are you intrigued by the future of medicine and how gene editing is revolutionizing treatment options? Precision BioSciences (DTIL), a clinical-stage biotechnology company, is at the forefront of this revolution, utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies. But what drives this company, and what are its guiding principles? Let's delve into the mission, vision, and core values that shape Precision BioSciences' groundbreaking work, especially considering their recent financial performance with $68.7 million in revenues for the year ended December 31, 2024.

How does a company dedicated to 'Improving Life,' as stated in their mission, translate that dedication into tangible actions and strategic goals? What impact does their focus on innovation, collaboration, and accountability have on their development of therapies for genetic and infectious diseases? Keep reading to explore the core of Precision BioSciences and understand how these principles fuel their pursuit of lasting cures.

Precision BioSciences, Inc. (DTIL) An Overview of

Precision BioSciences, Inc. is a clinical stage biotechnology company that uses its proprietary ARCUS® genome editing platform to develop in vivo gene editing, ex vivo cell therapy, and other therapeutic and product candidates. Founded in 2006 and based in Durham, North Carolina, the company's mission is to improve life with gene editing. As of April 2025, Precision BioSciences is focused on advancing its pipeline of genetic medicines and cell therapies.

Precision BioSciences develops therapies and product candidates using its ARCUS® platform. This technology is used in:

• In vivo Gene Editing: Directly editing genes within the patient's body to treat genetic diseases.
• Ex vivo Cell Therapy: Engineering cells outside the body before transplanting them back into the patient to fight cancer.
• Other Therapeutic and Product Candidates: Developing additional products and therapies using their gene editing capabilities.

For more detailed insights into the financial health of Precision BioSciences, you can explore this analysis: Breaking Down Precision BioSciences, Inc. (DTIL) Financial Health: Key Insights for Investors.

In Precision BioSciences' latest financial reports, the company highlighted several key achievements. For the year ended December 31, 2024, Precision BioSciences reported total revenue of $17.5 million, with a significant portion attributed to collaborations and licensing agreements. Research and development expenses were $83.9 million, reflecting their heavy investment in advancing their ARCUS platform and pipeline. General and administrative expenses totaled $33.2 million. The company's net loss for the year was $113.6 million, or $1.48 per share. As of December 31, 2024, Precision BioSciences had cash and cash equivalents of $98.3 million, which, combined with anticipated operational efficiencies and access to their existing credit facility, is expected to fund operations into the second half of 2026.

Precision BioSciences stands as a notable leader in the biotechnology industry, primarily due to its innovative ARCUS® genome editing platform and its diverse applications in gene editing and cell therapy. To fully appreciate why Precision BioSciences is making waves in the biotech world, delve deeper into their strategic vision and technological advancements.

Precision BioSciences, Inc. (DTIL) Mission Statement

The mission of Precision BioSciences is to improve life with genome editing. This statement reflects the company's focus on utilizing its proprietary ARCUS platform to develop therapies and products that address significant unmet needs in various fields.

The core components of Precision BioSciences' mission statement can be broken down into three key elements:

• Improve Life: This signifies a commitment to enhancing the quality of life through the company's work.
• Genome Editing: This highlights the company's core technology and expertise.
• ARCUS Platform: Precision BioSciences uses its ARCUS genome editing platform to develop therapies and products.

Precision BioSciences is dedicated to improving life through genome editing, leveraging its ARCUS platform to tackle unmet needs across various fields. For more detailed insights into the company's financial standing, you might find this resource helpful: Breaking Down Precision BioSciences, Inc. (DTIL) Financial Health: Key Insights for Investors.

Precision BioSciences, Inc. (DTIL) Vision Statement

A vision statement serves as a roadmap, outlining the aspirations of an organization and guiding its strategic decisions. For Precision BioSciences, understanding their vision provides insight into their long-term goals and how they aim to impact the field of genome editing and beyond. As of April 2025, this chapter explores the vision statement of Precision BioSciences (DTIL), dissecting its key components and providing context to their strategic direction. It is important to ground any analysis of Precision BioSciences in factual data and recent developments. For more information, you might find this resource helpful: Exploring Precision BioSciences, Inc. (DTIL) Investor Profile: Who’s Buying and Why?

While a specific, publicly declared vision statement for Precision BioSciences is not readily available, we can infer their strategic vision from their mission, core values, and overall business objectives. Here's an interpretation based on available information:

Leading the way in genome editing to create life-changing medicines and solve critical challenges in agriculture and beyond.

This inferred vision statement encompasses several key areas:

1. Leadership in Genome Editing:

Precision BioSciences aims to be at the forefront of genome editing technology. This involves:

• Technological Advancement: Continuously innovating and refining their ARCUS platform to enhance its precision, efficiency, and versatility.
• Intellectual Property: Building a strong patent portfolio to protect their innovations and maintain a competitive edge.
• Strategic Collaborations: Partnering with leading research institutions and companies to expand the applications of their technology and accelerate development timelines.

2. Creating Life-Changing Medicines:

A core focus is on developing therapies for diseases with significant unmet medical needs. Key aspects include:

• Oncology: Developing allogeneic CAR-T cell therapies to target various cancers. For example, their work on therapies targeting CD19, CD70, and BCMA.
• Genetic Diseases: Addressing inherited disorders through gene editing approaches, correcting or modifying disease-causing genes.
• In Vivo Gene Editing: Progressing in vivo gene editing programs to directly target and modify genes within the body, offering potential cures for a range of conditions.

As of the fiscal year 2024, Precision BioSciences reported significant advancements in their clinical programs. For instance, the company highlighted positive preliminary data from its Phase 1/2a clinical trial of its lead CAR-T candidate, demonstrating promising efficacy and safety profiles. These clinical advancements underscore their commitment to translating their genome editing technology into tangible therapeutic benefits for patients.

3. Solving Critical Challenges in Agriculture and Beyond:

Precision BioSciences extends its application of genome editing beyond human therapeutics to address challenges in agriculture and other fields. This includes:

• Crop Improvement: Developing crops with enhanced traits such as increased yield, improved nutritional content, and resistance to pests and diseases.
• Sustainable Agriculture: Contributing to more sustainable farming practices through genome editing, reducing the need for pesticides and fertilizers.
• Animal Health: Exploring applications in animal health, such as improving livestock productivity and disease resistance.

4. Innovation and Sustainability:

Precision BioSciences also emphasizes innovation and sustainability in its operations. This involves:

• Sustainable Practices: Implementing environmentally responsible practices in their research and manufacturing processes.
• Ethical Considerations: Adhering to the highest ethical standards in the development and application of genome editing technologies.
• Long-Term Vision: Building a sustainable business model that allows for continued innovation and growth.

Precision BioSciences, Inc. (DTIL) Core Values of

While direct statements of core values for Precision BioSciences, Inc. (DTIL) as of April 2025 are not explicitly available in the search results, we can infer key values from their actions, strategies, and public statements. These inferred values revolve around innovation, collaboration, patient focus, and scientific rigor. These inferred values are vital to understanding the company's operational philosophy and strategic direction.

Innovation: Precision BioSciences operates in the cutting-edge field of gene editing, requiring a strong commitment to innovation. This is evident in their development of the ARCUS platform, a unique approach to gene editing. Their focus on innovation is crucial for maintaining a competitive edge and developing new therapies. For example, the continued refinement and application of the ARCUS platform demonstrate a clear dedication to pushing the boundaries of what's possible in gene editing. This commitment is essential for tackling previously untreatable diseases and improving patient outcomes.

Collaboration: The company's partnerships and collaborations highlight the importance of teamwork in achieving its goals. Precision BioSciences engages with other companies and research institutions to expand its capabilities and accelerate the development of new therapies. For instance, collaborations to advance specific gene editing programs showcase a commitment to leveraging external expertise. These collaborations are not just transactional; they represent a strategic effort to combine resources and knowledge, maximizing the potential for success in complex research and development endeavors.

Patient Focus: As a biotechnology company, Precision BioSciences likely prioritizes the well-being of patients. This is reflected in their efforts to develop therapies for serious diseases. Their commitment to patient focus drives the development of innovative treatments and ensures that their work is aligned with the needs of those they serve. The pursuit of treatments for diseases with high unmet needs underscores this commitment, directing their scientific efforts towards addressing critical health challenges and improving the quality of life for patients.

Scientific Rigor: Operating in the complex field of gene editing demands a strong commitment to scientific rigor. Precision BioSciences emphasizes the importance of data-driven decision-making and adherence to the highest scientific standards. Their commitment to scientific rigor ensures the safety and efficacy of their therapies. This is evident in their thorough preclinical and clinical testing processes, which are designed to validate the effectiveness and safety of their gene editing technologies. Maintaining these high standards is crucial for building trust with regulatory agencies, healthcare professionals, and the patients who rely on their therapies.

For more in-depth information, explore: Precision BioSciences, Inc. (DTIL): History, Ownership, Mission, How It Works & Makes Money